A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated with Basal + Prandial Insulin

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

580

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

March 19, 2026

Study Completion Date

April 9, 2026

Conditions

Diabetes

Interventions

DRUG

GZR4

GZR4 s.c., once-weekly，treat-to-target dose

DRUG

Insulin Glargine U100 group

Insulin Glargine U100 s.c.,once-daily，treat-to-target dose